CA2300362A1 - Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie - Google Patents

Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie Download PDF

Info

Publication number
CA2300362A1
CA2300362A1 CA002300362A CA2300362A CA2300362A1 CA 2300362 A1 CA2300362 A1 CA 2300362A1 CA 002300362 A CA002300362 A CA 002300362A CA 2300362 A CA2300362 A CA 2300362A CA 2300362 A1 CA2300362 A1 CA 2300362A1
Authority
CA
Canada
Prior art keywords
vector
sequence
vector according
dna sequence
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300362A
Other languages
English (en)
Inventor
Christian Hofmann
Michael Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HepaVec AG fur Gentherapie
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2300362A1 publication Critical patent/CA2300362A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un vecteur de baculovirus modifié par coque de protéine s'utilisant en génothérapie et s'appliquant à la médecine, la biotechnologie et la technique génique. L'invention vise à la construction d'un vecteur de baculovirus présentant une stabilité élevée dans le sang, par modification de l'enveloppe virale et permettant de transférer et d'établir des gènes thérapeutiques, indépendamment de leur taille, dans des cellules mamméliennes, de manière hautement spécifique et efficace. Le vecteur doit pouvoir s'utiliser en génothérapie chez l'homme. Le vecteur obtenu selon l'invention comprend un virus d'insecte, de préférence un représentant des baculovirus ou d'un virus de la polyhédrose nucléaire, contenant les constituants suivants: des coques de protéines de virus modifiées, une séquence d'ADN thérapeutique, un promoteur adapté à l'expression génique et éventuellement une séquence d'établissement.
CA002300362A 1997-08-15 1998-08-05 Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie Abandoned CA2300362A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19735593.5 1997-08-15
DE1997135593 DE19735593C2 (de) 1997-08-15 1997-08-15 Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
PCT/DE1998/002255 WO1999009193A1 (fr) 1997-08-15 1998-08-05 Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie

Publications (1)

Publication Number Publication Date
CA2300362A1 true CA2300362A1 (fr) 1999-02-25

Family

ID=7839201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300362A Abandoned CA2300362A1 (fr) 1997-08-15 1998-08-05 Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie

Country Status (6)

Country Link
EP (1) EP1003896A1 (fr)
JP (1) JP2003530064A (fr)
CA (1) CA2300362A1 (fr)
DE (1) DE19735593C2 (fr)
ES (1) ES2150894T1 (fr)
WO (1) WO1999009193A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183993B1 (en) * 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002014527A2 (fr) 2000-08-11 2002-02-21 Boyce Thompson Institute For Plant Research, Inc. Baculovirus nuls gp64, pseudotypes a l'aide de proteines d'enveloppe heterologues
US20040146487A1 (en) 2001-03-12 2004-07-29 Airenne Kari Juhani Avidin pseudotyped viral vectors and their use
WO2002096469A2 (fr) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Transfert genique de vecteur viral
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
US6863884B2 (en) 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
US7416890B2 (en) 2002-09-25 2008-08-26 Osaka Industrial Promotion Organization Baculovirus vector, method of producing thereof and method of gene transfer
WO2004029259A1 (fr) * 2002-09-25 2004-04-08 Osaka Industrial Promotion Organization Vecteur de baculovirus, son procede de construction et procede de transfert genique
KR20070007086A (ko) 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
GB0425739D0 (en) * 2004-11-23 2004-12-22 Procure Therapeutics Ltd Humanised baculovirus 2
CA3005835C (fr) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
CA2594557C (fr) 2004-12-22 2016-04-26 Ambrx, Inc. Hormone de croissance humaine modifiee
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
GB2438760A (en) 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
SG165353A1 (en) 2005-06-03 2010-10-28 Ambrx Inc Improved human interferon molecules and their uses
WO2007059312A2 (fr) 2005-11-16 2007-05-24 Ambrx, Inc. Procedes et compositions comprenant des acides amines non naturels
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
ES2660000T3 (es) 2008-09-26 2018-03-20 Ambrx, Inc. Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
WO2010036964A2 (fr) 2008-09-26 2010-04-01 Ambrx Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2016059911A1 (fr) * 2014-10-17 2016-04-21 国立大学法人金沢大学 Vaccin antipaludéen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
EP0785803A4 (fr) * 1994-09-23 2000-08-02 Gen Hospital Corp Utilisation d'un virus a adn non mammalien en vue de l'expression d'un gene exogene dans une cellule mammalienne
US5750383A (en) * 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
DE19735593C2 (de) 1999-08-26
ES2150894T1 (es) 2000-12-16
DE19735593A1 (de) 1999-02-18
EP1003896A1 (fr) 2000-05-31
JP2003530064A (ja) 2003-10-14
WO1999009193A1 (fr) 1999-02-25

Similar Documents

Publication Publication Date Title
CA2300362A1 (fr) Vecteur de baculovirus modifie par coque de proteine s'utilisant en genotherapie
CA2148934C (fr) Particules vectorielles ciblables
JP3681752B2 (ja) 遺伝子治療に使用できる宿主 − ベクタ系
US20050181507A1 (en) Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP0851769B1 (fr) Therapie genique utilisant des vecteurs d'adenovirus ovins
WO2001058940A2 (fr) Capside adenovirale contenant une proteine ix chimere
IL214413A (en) Human Recombinant Human Adenovirus Type 35, Nucleic Acid Encoded, Nucleic Acid Cell and Method
JP2001522236A (ja) 改変アデノウイルスファイバーおよび標的アデノウイルス
US6872528B2 (en) Highly productive packaging lines
AU2002315947A1 (en) Adenoviral vectors with cell type specificity for mesenchymal cells
AU717202B2 (en) New variants of apolipoprotein A-I
US7410954B2 (en) Adenovirus serotype 30 (Ad30)
US5736360A (en) Endothelial cell tropic compositions and methods of making and using the same
AU729934B2 (en) Retroviral vector and its use in gene therapy
WO1998047916A1 (fr) Polypeptides bifonctionnels utilises dans le ciblage viral specifique en fonction des cellules
JP2000157289A (ja) 平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクタ―
AU747763B2 (en) Method for helper virus-free packaging of a gene vector DNA
CA2131415C (fr) Vecteur pour une therapie genique specifique du foie
US20020137213A1 (en) Adenovirus particles with mutagenized fiber proteins
EP1279738A1 (fr) Vecteurs de transfert de genes munis d'un tropisme pour des cellules souches mesenchymateuses
EP1195440A1 (fr) Vecteurs d'apport de genes pour les cellules souches
CA2047363C (fr) Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs
EP0870050A2 (fr) Virus exprimant des proteines toxiques, et lignees cellulaires productrices
Michael Development of tropism-modified adenoviral vectors for targeted gene delivery
Lea et al. The Scope of Viral Vectors for the Transduction of Haemopoietic Cells

Legal Events

Date Code Title Description
FZDE Discontinued